A previous study discovered that inhibiting glycolysis using 2-deoxy-d-glucose enhanced sensitivity to afatinib (a second-generation irreversible EGFR-TK) in NSCLC cells with acquired resistance due to the secondary EGFR T790M mutation [92]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.